Vital Signs - Will Drug and Gene Therapy Eradicate Angioplasty?

Vital Signs - Will Drug and Gene Therapy Eradicate Angioplasty?

 

RELEASE DATE
23-Oct-2006
REGION
North America
Research Code: 9561-00-19-00-00
SKU: HC00457-NA-MR_03929
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00457-NA-MR_03929

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on October 23, 2006, provides a strategic overview and discussion of the potential impact of drug and gene therapy on the amount of angioplasty procedures in clinical practice. Additionally, an emerging company profile is provided for Foxhollow Technologies Inc., a leader in the development and manufacturing of plaque excision devices for PAD. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of October 9 - October 13, 2006.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on October 23, 2006, provides a strategic overview and discussion of the potential impact of drug and gene therapy on the amount of angioplasty procedures in clinical practice. Additionally, an emerging company profile is provided for Foxhollow Technologies Inc., a leader in the development and manufacturing of plaque excision devices for PAD. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of October 9 - October 13, 2006.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-19-00-00
Is Prebook No